Stock listing
NASDAQ:IMA ImageneBio, Inc. Stock
Home listing (NASDAQ) of ImageneBio, Inc.
Follow ImageneBio, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:IMA
$3.92 USD +0.11 (+2.9%)
Close on Nov 20, 2026
- Day range
- $3.79 – $4.04 USDNov 20, 2026
- Volume
- 44,335 sharesNov 20, 2026
- Market cap
- $44.50M USDAt the close on Nov 20, 2026 · price × 11.35M shares outstanding
- 52-week range
- $3.01 – $7.60 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $69,688 USDMedian day 11,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:IMA · Home | $3.92 USD | +0.11 (+2.9%) | 44,335 | $4.04 | $4.04 | $3.785 | $3.81 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IMA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.92 | +0.11 | +2.9% | $4.04 | $4.04 | $3.785 | 44,335 | |
| $3.81 | -0.09 | -2.3% | $3.98 | $3.98 | $3.78 | 5,286 | |
| $3.90 | +0.70 | +21.9% | $3.20 | $4.10 | $3.005 | 90,385 | |
| $3.20 | -0.27 | -7.8% | $3.31 | $3.36 | $3.13 | 23,166 | |
| $3.47 | +0.02 | +0.6% | $3.50 | $3.579 | $3.338 | 4,024 | |
| $3.45 | -0.27 | -7.3% | $3.83 | $3.83 | $3.44 | 10,628 | |
| $3.72 | -0.09 | -2.4% | $3.81 | $3.85 | $3.71 | 3,869 | |
| $3.81 | -0.16 | -4.0% | $4.12 | $4.12 | $3.60 | 22,295 | |
| $3.97 | -0.135 | -3.3% | $4.12 | $4.30 | $3.89 | 14,659 | |
| $4.105 | -0.06 | -1.4% | $4.04 | $4.26 | $4.04 | 1,401 | |
| $4.165 | +0.065 | +1.6% | $4.00 | $4.165 | $4.00 | 15,944 | |
| $4.10 | +0.08 | +2.0% | $4.245 | $4.245 | $4.01 | 4,477 | |
| $4.02 | -0.07 | -1.7% | $3.89 | $4.127 | $3.89 | 9,063 | |
| $4.09 | -0.01 | -0.2% | $4.10 | $4.10 | $4.045 | 7,608 | |
| $4.10 | +0.05 | +1.2% | $4.05 | $4.21 | $4.05 | 5,671 | |
| $4.05 | -0.15 | -3.6% | $4.15 | $4.15 | $4.04 | 4,998 | |
| $4.20 | +0.18 | +4.5% | $4.02 | $4.45 | $4.02 | 24,093 | |
| $4.02 | -0.03 | -0.7% | $4.08 | $4.10 | $4.02 | 3,725 | |
| $4.05 | -0.17 | -4.0% | $4.15 | $4.42 | $3.88 | 32,900 | |
| $4.22 | +0.175 | +4.3% | $3.98 | $4.30 | $3.98 | 7,869 | |
| $4.045 | -0.04 | -1.0% | $4.08 | $4.115 | $4.045 | 6,187 | |
| $4.085 | -0.045 | -1.1% | $4.14 | $4.18 | $4.07 | 7,087 | |
| $4.13 | +0.13 | +3.2% | $4.00 | $4.29 | $3.98 | 22,004 | |
| $4.00 | -0.04 | -1.0% | $4.00 | $4.13 | $3.99 | 6,063 | |
| $4.04 | +0.01 | +0.2% | $4.15 | $4.15 | $4.00 | 9,800 | |
| $4.03 | -0.121 | -2.9% | $4.26 | $4.26 | $3.982 | 21,600 | |
| $4.151 | -0.089 | -2.1% | $4.20 | $4.20 | $4.14 | 20,800 | |
| $4.24 | -0.01 | -0.2% | $4.16 | $4.25 | $4.055 | 10,100 | |
| $4.25 | +0.01 | +0.2% | $4.29 | $4.29 | $4.00 | 28,100 | |
| $4.24 | -0.02 | -0.5% | $4.17 | $4.31 | $3.90 | 8,100 | |
| $4.26 | -0.35 | -7.6% | $4.48 | $4.48 | $4.00 | 30,100 | |
| $4.61 | +0.01 | +0.2% | $4.60 | $4.61 | $4.60 | 2,200 | |
| $4.60 | -0.10 | -2.1% | $4.70 | $4.72 | $4.60 | 13,700 | |
| $4.70 | +0.10 | +2.2% | $4.602 | $4.73 | $4.602 | 8,500 | |
| $4.60 | +0.02 | +0.4% | $4.685 | $4.685 | $4.557 | 7,800 | |
| $4.58 | 0.00 | 0.0% | $4.60 | $4.67 | $4.58 | 11,800 | |
| $4.58 | 0.00 | 0.0% | $4.58 | $4.63 | $4.58 | 9,400 | |
| $4.58 | -0.06 | -1.3% | $4.61 | $4.615 | $4.57 | 7,300 | |
| $4.64 | -0.08 | -1.7% | $4.845 | $4.845 | $4.64 | 2,200 | |
| $4.72 | +0.06 | +1.3% | $4.70 | $4.81 | $4.70 | 17,800 | |
| $4.66 | -0.18 | -3.7% | $4.82 | $4.82 | $4.65 | 3,700 | |
| $4.84 | -0.01 | -0.2% | $4.95 | $4.975 | $4.81 | 1,500 | |
| $4.85 | +0.04 | +0.8% | $4.765 | $5.02 | $4.765 | 8,500 | |
| $4.81 | -0.08 | -1.6% | $4.80 | $5.10 | $4.80 | 23,900 | |
| $4.89 | -0.13 | -2.6% | $5.18 | $5.24 | $4.64 | 77,100 | |
| $5.02 | +0.09 | +1.8% | $5.21 | $5.28 | $4.99 | 22,800 | |
| $4.93 | +0.01 | +0.2% | $5.175 | $5.18 | $4.88 | 20,400 | |
| $4.92 | -0.08 | -1.6% | $4.99 | $5.19 | $4.762 | 14,200 | |
| $5.00 | -0.08 | -1.6% | $5.22 | $5.39 | $4.995 | 15,000 | |
| $5.08 | +0.075 | +1.5% | $5.08 | $5.14 | $4.925 | 8,000 | |
| $5.005 | -0.005 | -0.1% | $5.02 | $5.30 | $4.93 | 22,400 | |
| $5.01 | -0.04 | -0.8% | $4.92 | $5.20 | $4.865 | 20,900 | |
| $5.05 | +0.20 | +4.1% | $4.98 | $5.285 | $4.89 | 27,500 | |
| $4.85 | -0.035 | -0.7% | $4.865 | $4.97 | $4.73 | 15,500 | |
| $4.885 | -0.075 | -1.5% | $4.89 | $4.94 | $4.81 | 12,000 | |
| $4.96 | -0.06 | -1.2% | $5.16 | $5.16 | $4.93 | 6,200 | |
| $5.02 | -0.08 | -1.6% | $5.16 | $5.16 | $4.965 | 12,500 | |
| $5.10 | -0.24 | -4.5% | $5.48 | $5.54 | $4.93 | 24,500 | |
| $5.34 | +0.01 | +0.2% | $5.35 | $5.35 | $5.32 | 4,600 | |
| $5.33 | -0.10 | -1.8% | $5.43 | $5.50 | $5.33 | 17,400 | |
| $5.43 | -0.12 | -2.2% | $5.659 | $5.659 | $5.365 | 9,900 | |
| $5.55 | -0.07 | -1.2% | $5.62 | $5.62 | $5.44 | 16,800 | |
| $5.62 | +0.11 | +2.0% | $5.68 | $5.70 | $5.55 | 13,600 | |
| $5.51 | -0.10 | -1.8% | $6.09 | $6.205 | $5.51 | 19,900 | |
| $5.61 | -0.08 | -1.4% | $5.75 | $5.75 | $5.61 | 3,500 |
Splits
1 split · NASDAQ:IMA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-12 | Consolidation |
- Ticker
- NASDAQ:IMA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
ImageneBio Reports Third Quarter 2026 Financial Results
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 24 slides
Latest news
ImageneBio Reports Third Quarter 2026 Financial Results
Nov 9, 2026
Closed $3.81 (-4.0%) on Nov 10, 2026
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 2, 2026
Closed $4.70 (+2.2%) on Oct 5, 2026
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
Sep 8, 2026
Closed $5.01 (-0.8%) on Sep 9, 2026
ImageneBio Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
Aug 18, 2026
Closed $5.68 (+1.8%) on Aug 18, 2026
ImageneBio Reports Second Quarter 2026 Financial Results
Aug 5, 2026
Closed $5.75 (+0.7%) on Aug 5, 2026
ImageneBio Appoints Matt Robbins as General Counsel
Jul 7, 2026
Closed $6.07 (+1.2%) on Jul 7, 2026
ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York
May 27, 2026
Closed $5.93 (-0.1%) on May 28, 2026
ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update
May 7, 2026
Closed $5.29 (-10.5%) on May 8, 2026
ImageneBio Announces $30 Million Private Placement
Apr 13, 2026
Closed $6.05 (+23.4%) on Apr 13, 2026
ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
Mar 10, 2026
Closed $6.07 (+2.5%) on Mar 10, 2026
ImageneBio, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 13 in the last 12 months · 16 in all · newest Nov 9, 2026 · oldest 2025
- Decks
- 5 decks · latest August 2026
Where ImageneBio, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:IMA · Home listing · This page | NASDAQ | United States | USD |
| BOATS:IMA | BOATS | United States | USD |
Valuation
Price/book 0.3× against a median of 5.1×: the lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$80.79M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.52
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| ImageneBio, Inc. · NASDAQ:IMA | US$44.50M | −US$80.79M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.52 |
| MegaPro Biomedical Co., Ltd. · TPEX:6827 | US$45.95M | US$43.30M | n/a | n/a | n/a | 7.0× | n/a | 0.0× | n/a |
| SunBio, Inc. · KRX:067370 | US$45.82M | US$42.92M | 14.2× | 4.6× | 8.9× | 2.0× | 34.6% | 0.0× | n/a |
| Apollomics Inc. · NASDAQ:APLM | US$45.28M | US$42.65M | n/a | 5.0× | n/a | n/a | −128.7% | n/a | 1.02 |
| Zelluna ASA · OSL:ZLNA | US$45.02M | US$38.83M | n/a | n/a | n/a | 5.1× | n/a | 0.0× | n/a |
| Oncoinvent ASA · OSL:ONCIN | US$44.76M | US$33.80M | n/a | 14.3× | n/a | 5.4× | −673.1% | 0.0× | n/a |
| Gain Therapeutics, Inc. · NASDAQ:GANX | US$44.50M | US$33.11M | n/a | n/a | n/a | 4.4× | n/a | 0.0× | 1.60 |
| Annovis Bio, Inc. · NYSE:ANVS | US$44.12M | US$41.30M | n/a | n/a | n/a | n/a | n/a | n/a | 2.53 |
| Arch Biopartners, Inc. · TSXV:ARCH | US$44.06M | US$44.06M | n/a | n/a | n/a | n/a | n/a | n/a | 0.94 |
| Spero Therapeutics, Inc. · NASDAQ:SPRO | US$43.23M | −US$63.10M | n/a | −1.5× | n/a | 55.4× | −71.0% | 2.0× | 1.68 |
| Eloxx Pharmaceuticals, Inc. · NASDAQ:ELOX | US$43.15M | −US$1.28M | n/a | n/a | n/a | 1.1× | n/a | 0.3× | n/a |
| Median of the others | US$44.63M | US$40.06M | 14.2× | 4.8× | 8.9× | 5.1× | −99.9% | 0.0× | 1.60 |
Forecasts
3 strong buy · 1 strong sell · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 18.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -3.42 · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Kristin Yarema | Chief Executive Officer and Director |
| Kurinji Pandiyan | Chief Strategy and Operations Officer |
| Renuka Sivendran | Chief Technical Officer |
Board
| Director | Role |
|---|---|
| Jonathan Wang | Director |
| Kristin Yarema | Chief Executive Officer and Director |
| Weiguo Su | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · After close | −4.0% |
| Q2 2026 | Aug 5, 2026 · Before open | +0.7% |
| Q1 2026 | May 7, 2026 · After close | −10.5% |
| Q4 2025 | Mar 10, 2026 | +1.5% |
| Q3 2025 | Nov 12, 2025 · Before open | −0.7% |
| Q2 2025 | Jul 24, 2025 | +3.6% |
| Q1 2025 | May 8, 2025 | +3.7% |
| Q4 2024 | Mar 6, 2025 | +6.7% |
| Q3 2024 | Nov 7, 2024 | +2.3% |
| Q2 2024 | Aug 9, 2024 | +0.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 | +3.1% |
| Q4 2023 | Mar 12, 2024 | −3.4% |
| Q3 2023 | Nov 9, 2023 | −64.7% |
| Q2 2023 | Aug 10, 2023 | +2.4% |
| Q1 2023 | May 15, 2023 | −12.0% |
| Q4 2022 | Mar 14, 2023 | +0.7% |
| Q3 2022 | Nov 7, 2022 | +1.3% |
| Q2 2022 | Aug 11, 2022 | 0.0% |
| Q1 2022 | May 12, 2022 | −1.1% |
| Q4 2021 | Mar 17, 2022 | +26.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 24 slides | August 2026 |
| Investor Presentation (November 2025) | Investor deck | 25 slides | Nov 19, 2025 |
| Investor Presentation (July 2025) | Investor deck | 36 slides | Jul 29, 2025 |
| Ikena Oncology — Merger or Acquisition (December 2024) | Merger or acquisition | 27 slides | Dec 23, 2024 |
| Technical Presentation | Technical | 13 slides |
Financings
| Raise | Date |
|---|---|
| Private placement of pre-funded warrants Announced: about US$30M · US$5.199 a share · Leerink Partners Dealers: Leerink Partners (lead) Buyers: Coastlands Capital; Trails Edge Capital Partners; Omega Funds; OrbiMed Use of proceeds: Further development of IMG-007 in alopecia areata and late-stage development activities in atopic dermatitis | Apr 13, 2026 |
| Private placement of common stock Closed: US$75M raised Buyers: Deep Track Capital; Foresite Capital; RTW Investments; BVF Partners L.P.; Blue Owl Healthcare Opportunities; Omega Funds; OrbiMed | Jul 25, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Ikena Oncology, Inc. Priced at US$16.00 a share on Mar 25, 2021.
- Price
- US$16.00 a share
- Shares offered
- 7,812,500 shares of common stock
- Offering size
- US$125 million
- Underwriters' option
- Up to 1,171,875 more shares
- Underwriters
- Jefferies, Cowen, Credit Suisse, William Blair · In the order on the cover
- Shares delivered
- On or about Mar 30, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jan 8, 2021 |
| Filed publicly | Mar 5, 2021 |
| Amended once | Mar 22, 2021 |
| Shares registered with an exchange | Mar 23, 2021 |
| Declared effective by the SEC | Mar 25, 2021 |
| Final prospectus, with the price | Mar 26, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Mar 26, 2021 |
| EFFECT · Notice that a registration is effective | Mar 25, 2021 |
| CERT · Exchange's certificate of listing | Mar 25, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Mar 23, 2021 |
| CORRESP · Letter to the SEC | Mar 23, 2021 |
| CORRESP · Letter to the SEC | Mar 23, 2021 |
| S-1/A · Registration statement, amended | Mar 22, 2021 |
| CORRESP · Letter to the SEC | Mar 12, 2021 |
| CORRESP · Letter to the SEC | Mar 5, 2021 |
| S-1 · Registration statement | Mar 5, 2021 |
All 15 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Feb 25, 2021 |
| DRSLTR · Letter to the SEC with a draft | Feb 11, 2021 |
| DRS/A · Draft registration statement, amended | Feb 11, 2021 |
| UPLOAD · Letter from the SEC | Feb 8, 2021 |
| DRS · Draft registration statement | Jan 8, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Mar 26, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 800.0K | 3.50M | 9.16M | 15.6M | 31.0M | 9.19M | 13.8M | 990.0K |
| Cost of revenue | 1.03M | 1.53M | 1.02M | 64.3M | 47.1M | 44.8M | 24.9M | 39.0M |
| Gross profit | -233.0K | 1.97M | 8.14M | -48.7M | -16.1M | -35.7M | -11.2M | -38.0M |
| Research and development | 28.5M | 32.1M | 59.7M | 64.3M | 47.1M | 44.8M | 24.9M | 38.6M |
| Selling, general and administrative | 20.7M | 8.39M | 24.9M | 22.2M | 18.0M | 8.87M | 7.31M | 2.90M |
| Operating income | -48.5M | -37.0M | -75.4M | -70.9M | -34.1M | -44.5M | -18.5M | -40.9M |
| Depreciation and amortization | 400.0K | 1.10M | 1.02M | 751.0K | 544.0K | 300.0K | 243.0K | 422.0K |
| EBITDA | -48.1M | -35.9M | -74.4M | -70.2M | -33.6M | -44.2M | -18.2M | -40.5M |
| Income before tax | -45.7M | -36.6M | -68.3M | -68.8M | -34.1M | -44.3M | -16.8M | -40.9M |
| Income tax | -350.0K | 13.0K | -162.0K | 0 | 0 | 71.1K | ||
| Net income | -45.3M | -36.6M | -68.2M | -68.8M | -34.1M | -44.3M | -16.8M | -40.9M |
| Earnings per share, basic | -9.64 | -22.10 | -1.63 | -1.90 | -1.22 | -16.00 | -5.63 | -13.68 |
| Earnings per share, diluted | -9.64 | -22.10 | -1.63 | -1.90 | -1.22 | -16.00 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 94.5M | 12.1M | 119.9M | 59.9M | 232.2M | 162.5M | 82.1M | 18.2M |
| Short-term investments | 40.8M | 0 | 55.6M | 97.0M | ||||
| Receivables | 1.30M | |||||||
| Current assets | 140.3M | 12.5M | 178.7M | 160.0M | 236.5M | 166.0M | 85.2M | 20.0M |
| Property, plant and equipment | 0 | 8.00K | 2.33M | 3.21M | 2.44M | 1.39M | ||
| Total assets | 153.0M | 15.9M | 192.1M | 172.3M | 247.9M | 168.4M | 86.0M | 20.7M |
| Accounts payable | 1.44M | 5.29M | 2.07M | 2.09M | 2.38M | 2.12M | 935.0K | 2.27M |
| Current liabilities | 11.2M | 17.2M | 14.2M | 21.5M | 27.2M | 28.3M | 24.3M | 3.82M |
| Total debt | 9.99M | 7.52M | 10.7M | 5.69M | 6.99M | 186.0K | 78.9M | 62.6M |
| Total liabilities | 19.8M | 17.4M | 22.3M | 25.3M | 40.0M | 63.5M | 147.4M | 66.5M |
| Shareholders' equity | 133.1M | -160.6M | -126.1M | 147.0M | 207.9M | -101.0M | -61.5M | -45.8M |
| Shares outstanding | 12.5M | 48.3M | 48.3M | 36.3M | 36.0M | 3.10M | 2.99M | 2.99M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -47.8M | -21.3M | -79.7M | -74.1M | -60.3M | -37.8M | 47.9M | -11.6M |
| Capital spending | 0 | 0 | -414.0K | -1.43M | -1.76M | -766.0K | -316.0K | -305.0K |
| Free cash flow | -47.8M | -46.0M | -80.2M | -75.5M | -62.0M | -38.6M | 47.6M | -11.9M |
| Cash from investing | -5.81M | 11.1M | 64.1M | -99.3M | -1.76M | 2.92M | -316.0K | 11.0M |
| Cash from financing | 135.5M | 6.91M | 76.0M | 1.09M | 131.7M | 116.2M | 16.3M | |
| Share buybacks | -663.0K | -57.0K | ||||||
| Change in cash | 82.4M | -3.20M | 60.4M | -172.3M | 69.7M | 81.3M | 63.9M | -639.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Aug 12, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Aug 12, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Aug 7, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Aug 5, 2026 | Offer document | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-3 · Registration statement | Aug 5, 2026 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Aug 5, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Aug 5, 2026 | Offer document | SEC |
| S-3 · Registration statement | Aug 5, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2026 | Results | SEC |
| 3 · Initial statement of ownership | Jul 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 28, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Jul 23, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 23, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jul 20, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Jun 29, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 26, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Jun 17, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 17, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | May 7, 2026 | Offer document | SEC |
| 424B3 · Prospectus | May 7, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 30, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 29, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 21, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Apr 21, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Apr 20, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Apr 13, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 13, 2026 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Apr 6, 2026 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Apr 2, 2026 | Offer document | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 17, 2026 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Mar 10, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 10, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 10, 2026 | Results | SEC |
| 3 · Initial statement of ownership | Feb 20, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Feb 17, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 17, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Dec 18, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 18, 2025 | Management or board change | SEC |
| 8-K · Current report | Nov 19, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Nov 12, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Nov 12, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 3 · Initial statement of ownership | Nov 7, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Nov 5, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 5, 2025 | Management or board change | SEC |
| 424B3 · Prospectus | Oct 30, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 29, 2025 | Material contract | SEC |
| 8-K · Current report | Oct 22, 2025 | Management or board change | SEC |
| 8-K · Current report | Oct 10, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Oct 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 10, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Sep 16, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 11, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 11, 2025 | Other filings | SEC |
| S-1 · Registration statement | Sep 8, 2025 | Offer document | SEC |
| 4 · Change in ownership | Aug 15, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 15, 2025 | Insider trade | SEC |
| 8-K/A · Current report, amended | Aug 12, 2025 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Aug 7, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 5, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 4, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 4, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 1, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 30, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 29, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 29, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 29, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 29, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jul 29, 2025 | Acquisition or disposal | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 28, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jul 25, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Jul 24, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 24, 2025 | Current report | SEC |
| 8-K · Current report | Jul 22, 2025 | Current report | SEC |
| D | Jul 18, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 16, 2025 | Management or board change | SEC |
| 8-K · Current report | Jul 15, 2025 | Management or board change | SEC |
| 425 | Jul 11, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 11, 2025 | Current report | SEC |
| 425 | Jul 1, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 1, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 18, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Jun 16, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Jun 12, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Jun 11, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jun 10, 2025 | Other filings | SEC |
| S-4/A · Registration statement, amended | Jun 9, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jun 9, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 3, 2025 | Other filings | SEC |
| S-4/A · Registration statement, amended | May 30, 2025 | Offer document | SEC |
| S-4/A · Registration statement, amended | May 20, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| CORRESP · Letter to the SEC | May 7, 2025 | Other filings | SEC |
| S-4/A · Registration statement, amended | May 7, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | May 2, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 21, 2025 | Other filings | SEC |
| S-4/A · Registration statement, amended | Apr 21, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Apr 14, 2025 | Other filings | SEC |
| S-4 · Registration statement | Mar 18, 2025 | Offer document | SEC |
| ARS · Annual report to shareholders | Mar 6, 2025 | Annual report | SEC |
| 10-K · Annual report | Mar 6, 2025 | Annual report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2025 | Big-stake notice | SEC |
| 425 | Jan 10, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 31, 2024 | Big-stake notice | SEC |
| 425 | Dec 23, 2024 | Other filings | SEC |
| 8-K · Current report | Dec 23, 2024 | Material contract | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jul 12, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 10, 2024 | Meeting outcome | SEC |
| 8-K · Current report | May 28, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 13, 2024 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 26, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 12, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 12, 2024 | Annual report | SEC |
| SC 13G/A · Big-stake notice, amended | Mar 11, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 5, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 21, 2024 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 18, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2023 | Results | SEC |
| SC 13G · Big-stake notice | Oct 19, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Oct 11, 2023 | Meeting outcome | SEC |
| DEF 14A · Proxy statement | Sep 25, 2023 | Meeting notice | SEC |
| 4/A · Change in ownership, amended | Sep 21, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Sep 21, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 21, 2023 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Sep 15, 2023 | Meeting notice | SEC |
| 4 · Change in ownership | Sep 14, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 14, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 14, 2023 | Big-stake notice | SEC |
| 424B5 · Prospectus | Sep 12, 2023 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 11, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 6, 2023 | Other filings | SEC |
| D | Aug 18, 2023 | Other filings | SEC |
| S-3 · Registration statement | Aug 18, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 10, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2023 | Acquisition or disposal | SEC |
| 8-K · Current report | Jun 30, 2023 | Current report | SEC |
| 4 · Change in ownership | Jun 13, 2023 | Insider trade | SEC |
This page holds 200 of 339 filings. Open Filings
Cap table
Built by 6ix from ImageneBio, Inc.’s releases · as of Sep 30, 2026
- Common shares
- 11,351,456
- Fully diluted
- 11,351,456
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 11,351,456 | Sep 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 11,351,456 |
| Sep 30, 2026 | 12,456,281 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jean-François Formela Other companies: Korro Bio, Inc. (Co-Founder & Director · Since at least Nov 3, 2023); Translate Bio Inc (Director · Jun 27, 2018 – Sep 14, 2021 · Past); Spero Therapeutics, Inc. (Director · Nov 1, 2017 – Aug 17, 2021 · Past); Intellia Therapeutics, Inc. (Director · May 5, 2016 – Jun 14, 2022 · Past); Egalet Corporation (Director · Feb 5, 2014 – Feb 11, 2014 · Past); Oruka Therapeutics, Inc. (Director · Feb 10, 2012 – Oct 22, 2012 · Past); Horizon Pharma PLC (Director · Jul 28, 2011 – Mar 2, 2012 · Past) | Director · Mar 25, 2021 – Jun 7, 2024 · Past |
| David Bonita Other companies: Windward Bio Group AG (Director · Since at least Nov 16, 2026); Third Harmonic Bio Inc. (Director · Since at least Aug 11, 2025); Prelude Therapeutics Incorporated (Director · Since at least Jun 12, 2025) | Director · Since at least Jul 25, 2025 |
| Maria Koehler Other companies: ARS Pharmaceuticals, Inc. (Director · Mar 12, 2021 – Jun 10, 2022 · Past); Repare Therapeutics Inc (EVP, CHIEF MEDICAL OFFICER · Jun 18, 2020 – Mar 12, 2025 · Past) | Director · Apr 15, 2021 – Jun 7, 2024 · Past |
| Erin Butler Other companies: Armata Pharmaceuticals, Inc. (Vice President,Finance & Admin · Jul 1, 2022 – Jul 1, 2022 · Past) | Principal Accounting Officer · Since at least Jul 25, 2025 |
| Jotin Marango Other companies: Aptose Biosciences Inc (Senior VP, CFO, and CBO · Jun 3, 2019 – Jan 18, 2022 · Past) | Chief Financial Officer · Since at least Apr 25, 2022 |
| Sergio L Santillana Other companies: Merrimack Pharmaceuticals Inc (Chief Medical Officer · Jun 12, 2017 – Dec 11, 2018 · Past) | Chief Medical Officer · Mar 25, 2021 – Jan 3, 2023 · Past |
| Yanina Grant-Huerta Other companies: Atara Biotherapeutics, Inc. (Chief Accounting Officer · Since at least May 18, 2026) | Chief Financial Officer · Since at least Aug 14, 2026 |
| Jeffrey Ecsedy | Chief Development Officer · Mar 25, 2021 – Feb 1, 2024 · Past |
| Jonathan Wang | Director · Since at least Jul 25, 2025 |
| Kristin Yarema | Chief Executive Officer and Director · Since at least Aug 17, 2026 |
All 19 people
| Person | Seat |
|---|---|
| Kurinji Pandiyan | Chief Strategy and Operations Officer · Since at least Nov 12, 2025 |
| Mark Manfredi | President & CEO, Director · Mar 25, 2021 – Feb 1, 2024 · Past |
| Matt Robbins | General Counsel · Jul 7, 2026 – Nov 5, 2026 · Past |
| Maude Tessier | Chief Business Officer · Mar 25, 2021 – Feb 2, 2022 · Past |
| Renuka Sivendran | Chief Technical Officer · Since at least Nov 12, 2025 |
| Robert B Lally | Principal Accounting Officer · Since at least Jul 16, 2026 |
| Stephen Hui Wang | Director · Since at least Jul 25, 2025 |
| Weiguo Su | Director · Since at least Nov 5, 2026 |
| Yufang Lu | Chief Medical Officer · Since at least Jul 25, 2025 |
Log in to ask 6ix AI your own questions about ImageneBio, Inc.